FOURIER Substudy May Help Refute 'Dr. Google'
ACC.17 | WASHINGTON, DC — Reaching very low LDL levels with a PCSK9 inhibitor was not associated with any increase in neurocognitive adverse events, according to the largest and most rigorous study to assess the topic to date. Read More >>>
Keywords: ACC17, ACC Annual Scientific Session
< Back to Listings